TY - JOUR
T1 - Autoimmune hemolytic anemia and red blood cell autoantibodies
AU - Quist, Erin
AU - Koepsell, Scott
N1 - Publisher Copyright:
Copyright © 2015 College of American Pathologists.
PY - 2015/11
Y1 - 2015/11
N2 - Autoimmune hemolytic anemia is a rare disorder caused by autoreactive red blood cell (RBC) antibodies that destroy RBCs. Although autoimmune hemolytic anemia is rare, RBC autoantibodies are encountered frequently and can complicate transfusion workups, impede RBC alloantibody identification, delay distribution of compatible units, have variable clinical significance that ranges from benign to life-threatening, and may signal an underlying disease or disorder. In this review, we discuss the common presenting features of RBC autoantibodies, laboratory findings, ancillary studies that help the pathologist investigate the clinical significance of autoantibodies, and how to provide appropriate patient care and consultation for clinical colleagues. Pathologists must be mindful of, and knowledgeable about, this entity because it not only allows for direct clinical management but also can afford an opportunity to preemptively treat an otherwise silent malignancy or disorder.
AB - Autoimmune hemolytic anemia is a rare disorder caused by autoreactive red blood cell (RBC) antibodies that destroy RBCs. Although autoimmune hemolytic anemia is rare, RBC autoantibodies are encountered frequently and can complicate transfusion workups, impede RBC alloantibody identification, delay distribution of compatible units, have variable clinical significance that ranges from benign to life-threatening, and may signal an underlying disease or disorder. In this review, we discuss the common presenting features of RBC autoantibodies, laboratory findings, ancillary studies that help the pathologist investigate the clinical significance of autoantibodies, and how to provide appropriate patient care and consultation for clinical colleagues. Pathologists must be mindful of, and knowledgeable about, this entity because it not only allows for direct clinical management but also can afford an opportunity to preemptively treat an otherwise silent malignancy or disorder.
UR - http://www.scopus.com/inward/record.url?scp=84945893761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945893761&partnerID=8YFLogxK
U2 - 10.5858/arpa.2014-0337-RS
DO - 10.5858/arpa.2014-0337-RS
M3 - Review article
C2 - 26516943
AN - SCOPUS:84945893761
SN - 0003-9985
VL - 139
SP - 1455
EP - 1458
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 11
ER -